Stem Cell Network   Report issue

Foundation Phase 1 Phase 2
Founded: Ottawa Canada (2001)

Organization Overview

First Clinical Trial
2018
NCT03369275
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Stem Cell Network | Stem Cell Network (SCN)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Bronchopulmonary Dysplasia (Phase 1)

Hyperplasia (Phase 1)

Inflammation (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Pathologic Processes (Phase 2)

Preleukemia (Phase 2)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Shock (Phase 2)

Shock, Septic (Phase 2)

Syndrome (Phase 1)

Systemic Inflammatory Response Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4